Fig. 6: S76.T (CD5L)-aptamer blocks resistance to anti-VEGF therapy.
From: Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L
A Mouse adaptive resistance tumor model. S76.T-aptamer was injected intravenously every 3 days starting on day 38, after 21 days of B20 treatment. B Photographs of representative mice treated with scramble aptamer, scramble aptamer + B20, CD5L aptamer (S76.T) + IgG, and S76.T + B20. C, D Tumor weight (g) and the number of tumor nodules. E, F CD31 immunohistochemical (E) and Ki67 immunohistochemical (F) staining of tumors from scramble aptamer, B20, S76.T, and combination of S76.T + B20 treated mice (scale bar = 100 µm). For statistical analysis, five randomly selected tumors per group were stained, and five random fields per tumor were scored. Data represented as mean values ± SD determined by the ordinary one-way ANOVA Tukey’s multiple comparisons test; n = 5 for both C & D; for D; n = 4 for E and F.
